ORYN THERAPEUTICS, Inc.
Robert Erwin serves as the Chief Executive Officer of Oryn Therapeutics, Inc. since 2020, leading a clinical-stage company dedicated to innovative drug development through Orynotides for treating inflammatory, infectious, and auto-immune diseases. Previously, Robert held the position of President at the Marti Nelson Cancer Foundation, a patient advocacy organization, from 1994 to 2022. Additionally, Robert was the Chairman of Novici Biotech LLC from 2007 to 2021 and served as President of iBio, Inc. from 2007 to 2020, with the latter focusing on plant-based protein manufacturing for vaccines. Robert's earlier roles include Managing Director of Bio-Strategic Directors LLC and Chairman positions at Icon Genetics AG and Large Scale Biology Corporation. Robert earned a Master of Science in Genetics from Louisiana State University between 1972 and 1978.
This person is not in any teams
This person is not in any offices
ORYN THERAPEUTICS, Inc.
Oryn Therapeutics is a clinical-stage company developing a new class of drug candidates, Orynotides. These proprietary drug candidates are engineered, stable, cyclic peptides with very low immunogenicity and toxicity. They modulate pathologic inflammation and have proven effective in animal models of autoimmune and chronic inflammatory diseases such as rheumatoid arthritis and ulcerative colitis. They have proven effective in preclinical cancer models and augment natural host defense, functioning as host-directed anti-infectives against drug resistant pathogens.